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Plasmodiumvivaxhas not beenestabOptimaltherapyfor infectionby chloroquine-resistant
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separatestudies,147 Javaneseresidentsof IrianJaya
during
infectedby P. vivaxweretreatedwitheitherchloroquine(25 mg of base/kgduring3 daysor 10
mg of base/kgin one dose)plus primaquine(10 mg/kg during28 daysor 2.5 mg/kg during3
(24 mgbase/kgin 12 h;n = 19).
days)(n = 78), chloroquineplusplacebo(n = 50), orhalofantrine
Therewas no differencein toleranceto or sideeffectsof anyof the regimens.Within14 daysof
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startingtherapy,therapeuticfailureamong these patientswas 4407ofor chloroquine,50Zo
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days,
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and60Zo,
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respectively.Thus,chloroquineplusprimaquinein combipeuticfailurewas7807o,
P. vivax.
nationand halofantrinealoneareeffectivetherapiesfor chloroquine-resistant
Resistance to chloroquineby Plasmodiumvivaxoccurs in
SoutheastAsia and the southwest Pacificregion [1,2]. The
infection develops despite standard chloroquine prophyReceived 26 September 1994; revised7 February1995.
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laxis, and parasitemiapersistsor recurswithin 14 days after
initiationof standardchloroquinetherapy.Alternativedrugs
for chloroquine-resistantP. vivaxhave not been evaluated.
Resistanceto chloroquineby P. vivaxin the absence of specific therapiesknown to be effective threatensthe health of
the millions of people exposed to this infection. We investigated chloroquine plus primaquine in combination and
halofantrine alone as therapies for chloroquine-resistant
P. vivax.
Materials and Methods
Studysitesandsubjects. BetweenJuly 1992andJune 1994,
studiesweredone at threevillagesin the Arso regionof northeasternIrianJaya,Indonesia,whereP. vivaxis endemic[3]. The
villageswere 7- to 18-month-oldsettlementsof people from
Javaand otherislands.Subjectswere^6 yearsold withasexual
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of P. vivaxdemonstrableby lightmicroscopy(MO
weekwassubtractedfromthe denominatorusedto calculatethe
parasitemias
asexual parasites//uL
of blood) of Giemsa-stainedblood films cumulativeincidence.The 14- or 28-daycumulativeincidence
readby experiencedmicroscopists.A historyof recentchloro- of therapeuticfailurewas calculatedusing standardlife table
calculationsof weeklyintervals[4].
quineconsumptiondidnot disqualifysubjects.All subjectswere
screenedforglucose-6-phosphate
usdehydrogenase
deficiency
ing an NADPHspot test (Sigma,St. Louis).
Results
StudiesI and II. Two studiesof identicaldesignweredone
at two villagesin 1992and 1993.PatientsinfectedwithP. vivax
receivedstandardchloroquine(25 mg/kgin threedosesover48
Studysubjects. Among chloroquineplus placebo,chloro=
and
a
of
standard
h)
placebo primaquine(n 27),
chloroquine quine (25 mg/kg) plus primaquine,and chloroquine(10 mg/
therapyplus 0.5 mg/kgprimaquinebase daily for 14 days folkg) plus primaquinegroupsin studies I and II, subjectswere
lowedby 0.5 mg/kgprimaquine
on alternatedaysfor 13 days(a
predominantlymale (23 vs. 7 female, 23 vs. 4, 25 vs. 1,
= 30), or 10 mg/kgchloroquinebase in a
singledose plus the
respectively)and rangedin age from 6 to 51 years (means,
regimenof primaquineabove (n = 26). On day 0, all subjects 24, 21, and 23, respectively;P = .222). Geometric mean
begantherapywithchloroquine(P.T. BayerIndonesia,Jakarta; parasitecounts were 650, 1307, and 1618
trophozoites/ziL
uncoatedtablets,150 mg of base).Receiptof dailyprimaquine
= .123),
Eleven of the 83 subjectshad mixed
(P
respectively.
New York;sugar-coatedtablets, 15 mg of
(Sanofi-Winthrop,
infectionswith P.falciparumand P. vivaxat enrollment.Figbase)or dailyplacebo(starchand amylose;KimiaFarma,Banure 1A shows the mean levels of chloroquine in blood at
dung, Indonesia)was randomizedby blindlydrawinga coded
card. The code was unknownto subjectsand to the research enrollmentand on day 2 among groups.
team.
Among chloroquine plus placebo, chloroquine (25 mg/
A bloodfilmforparasitologic
examinationanda 100-;iLblot
kg) plus primaquine(2.5 mg/kg), and halofantrinegroupsin
of bloodon filterpaper(no. 1;Whatman,Clifton,NJ) forassay
studyIII,subjectswere predominantlymale (17 vs. 5 female,
of chloroquinewerecollectedbeforeadministration
of the first
17 vs. 6, and 12 vs. 7, respectively)and rangedin age from7
dose of chloroquineon day0. A second IOO-/1L
blotof capillary to 54 years(means, 26, 27, and 27,
respectively;P = .311).
bloodwascollectedon day2, 4 h afteradministration
of the last
Geometric mean parasitecounts were 608, 555, and 367
doseof chloroquine.Studysubjectswereexaminedon days0, 1,
trophozoites/juL(P = .1821), respectively.Five of the 64
2, 4, 7, 11, 14, 18, 21, 25, and 28 or at any timethattheyagain
subjectshad mixed infectionswith P.falciparumand P. vivax
exhibitedsymptomsof malaria.Symptomaticpatients(chills,
at enrollment. Figure 1B shows the mean levels of chlorofever,or malaise)with detectableparasitemiawere given quinine therapyafterobtaininga 100-jliL
blotof bloodformeasure- quine in blood at enrollmentand on day 2 among groups.
mentof bloodchloroquinelevels.
Posttherapeuticparasitemias. All subjects in studies I
and II receivingchloroquineplus primaquinecleared paraStudyIII. Basedon resultsof studiesI and II, a thirdstudy
was done in the Arso regionin 1994. Patientswith P. vivax sitemiaswithin 5 days. Four patients receivingchloroquine
parasitemiawererandomizedto receiveeitherstandardchloroplus placebo had asexual parasitemiasthat failed to clear by
quineplusthreedosesof placeboduring48 h (n ^ 23), standard day 7.
chloroquineplusthreedoses(two 1.0 mg/kg,one 0.5 mg/kg)of
All patients in study III cleared asexual parasitemiasby
primaquinebase at 24-h intervals(n = 22), or threedoses of
day 4, and none reappearedby day 7. The first recurrent
halofantrine(n = 19; SmithKlineBeecham,UK; 500 mg of
on
11 in 2 patientswho received
base, uncoatedtablet)at 6-h intervals.Subjectswere followed parasitemiasappeared day
chloroquineplus placebo.
for 28 daysand sampledas in studiesI and II.
Table 1 summarizesthe cumulativeincidence analysisof
in
blood.
Collection
and
of
Assay of chloroquine
analysis
P.
vivaxtherapeuticfailureamong subjectsin the studies 14
whole blood specimensfor chloroquineand desethylchloroand
28 days after the start of therapy.The relative risk of
quine was done as described[3] usinghigh-performance
liquid
Richmond,CA).
therapeuticfailureamong subjects taking chloroquine plus
(Bio-RadLaboratories,
chromatography
outcome.
Persistence
or
recurrence
of
Analysisof therapeutic
placebo was 8-fold higher than that among patients given
P. vivaxparasitemiawithin 28 days afterstartingtherapywas
chloroquine plus primaquineat both day 14 and day 28.
considereda therapeuticfailure.The cumulativeincidenceof
When the data from the studieswere combined, the 14-day
therapeuticfailurewithingroupsandthe ratioof incidencedencrudefailurerate,which excludeswithdrawalsfromthe analsity (relativerisk) among groupssummarizedoutcomes.The
ysis, was 44*30
among the 48 subjectsgiven standardchlorosignificanceof the relativerisksand confidenceintervalswas
57camong the 74 subjectsgiven primaquine,
quine
therapy,
obtainedusingEpistat5.01b (CDC, Atlanta;WHO,Geneva).
and
0
the
19 subjectsgiven halofantrine.The 28-day
among
The significanceof differencesbetween means (geometric
crude
failure
rate
was
78# among the 45 subjectsgiven stanmean, log-transformed
data) was estimatedby the two-tailed
dard
Student'st test.
chloroquinetherapy, 157camong the 68 subjectsgiven
with
intercurrentPlasmodium
Subjects
falciparumparasite- primaquine,and 67camong the 17 subjectsgiven halofantrine.
mia remainedin the analysisof the cohortup to the point of
In
these
the
of
0.5
instances,
quininetherapy.
product
Symptomsandsignsaftertreatment. Therewas no indica(assumed
midintervalwithdrawal)and the numberof withdrawalsper
tion that any treatmentregimen was associatedwith more
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Figure 1. Measurementsof chloroquineand desethylchloroquineamong treatmentgroups in studies I and II (A) and III (B). Points at
=
days 0 and 2 representmean (?SD) chloroquine -I-desethylchloroquinelevel of groups(n 17-22). All other points representmeasurements of chloroquine4- desethylchloroquineafteronset of recurrentP. vivaxparasitemiaamong individualsubjects.CQ, chloroquine;PQ,
primaquine;PL, placebo; HF, halofantrine.Numbersin parenthesesreferto total doses (mg/kg).

side effectsthan any other regimen.Malaise,fever, chills, or
headache persistedthrough the 48 h after startingtherapy
among 20%(6/30), 23%(6/26), and 22%(6/27) of subjects

receivingchloroquineplus placebo, chloroquine(25 mg/kg)
plus primaquine,and chloroquine (10 mg/kg) plus primaquine in studies I and II. There were also no differencesin

Table 1. Treatmentof chloroquine-resistantP. vivaxwith chloroquine,chloroquineplus primaquine,or halofantrine.
14 days

Study, treatment
regimen(n)
Studies I and II
CQ25+ PL(27)
CQ25+ PQ.o (30)
CQ.o + PQ10(26)
Study III
CQ25+ PL(23)
CQ25+ PQ2.5(22)
HF(19)

28 days

withdrawing

No. with
treatment
failure

CIF
(%)

RR(95%CI)

P*

2
2
1

14
2
2

53
7
8

8.38(1.7-27.0)
7.63(0.7-18.0)

0
1
0

7
0
0

31
7
8

No.

withdrawing

No. with
treatment
failure

CIF
(%)

RR(95%CI)

P*

.021
.004

4
4
3

20
4
3

80
15
13

7.69(4.5-14.0)
8.33(4.5-17.0)

<.001
<.001

.015
.036

1
3
2

15
3
1

69
16
6

No.

>7.0?
>7.0?

5.00(2.9-9.0)
12.5(5.3-33.0)

<.001
<.001

NOTE. CQ, chloroquine;PL, placebo; PQ, primaquine;HF, halofantrine;subscriptnumbers refer to total dose (mg/kg). Withdrawalswere due to
intercurrentparasitemiaby Plasmodiumfalciparum;treatmentfailure,persistentor recurrentparasitemiaby P. vivax.CIF, 14-or 28-day cumulativeincidence
of therapeuticfailure.RR, riskof parasitemiain placebo group relativeto PQ or HF groups(CI, confidence interval).
* Calculated two-tailedFisher'sexact test.
by
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relief of symptomsamong the groups in study III (data not
shown). Incidence density analysis revealed no differences
among treatmentregimensfor overall symptomsduringthe
remainderof the 28-day test (P = .298).
bloodlevels. Figure
Chloroquineand desethylchloroquine
1 illustratesthe sum of chloroquineand desethylchloroquine
levels in whole blood beforechloroquinetherapy(day 0), 4 h
afterthe last dose of supervisedchloroquinetherapy(day 2),
and after the onset of recurrentparasitemia(days 7-28). At
the time of enrollment,many subjectswith P. vivaxparasitemia had levels of chloroquine in their blood considered
therapeutic (53% had MOO ng/mL chloroquine plus
desethylchloroquine).Subjects had normal absorption of
chloroquine (456-6257 ng/mL chloroquine plus desethylchloroquineat day 2; mean, 1932). Chloroquinelevels before and after therapywere similarin the chloroquineplus
primaquineand chloroquineplus placebogroups(P = .578).
The day 2 mean level of chloroquine plus desethylchloroquine among subjectswho received only 10 mg/kg chloroquine was indistinguishablefrom that among patients who
received 25 mg/kg chloroquineplus primaquineor placebo
(P = .3422). Most therapeuticfailuresoccurredwith MOO
ng/mL chloroquine plus desethylchloroquine in whole
blood. Ratios of chloroquineto desethylchloroquine(mean,
3.1) did not differbetweenprimaquineand placeboon day 2
in studies I and II (P = .450) or III (P = .558).
Discussion
These studiesdemonstratethatthe combinationof 25 mg/
kg chloroquinebase and 2.5 mg/kg primaquinebase administeredin three divideddoses during48 h or 24 mg/kg halofantrinebase administeredin threedivideddoses during 12 h
is effective treatmentfor chloroquine-resistantP. vivaxmalaria in Irian Jaya, Indonesia. The data also show that the
chloroquine plus primaquinecombination is as well-tolerated as chloroquine alone. The rate of therapeuticfailure
after treatmentwith a single dose of 10 mg/kg chloroquine
base plus primaquinewas similarto the resistanceto 25 mg/
kg chloroquineplus primaquinetherapy.However, the levels of chloroquine on day 2 were similar between these
groups, presumablybecause of the relativelyhigh levels of
chloroquinein the blood of most volunteerson day 0 due to
self-medication.Therefore,we cannot conclude that a single
dose of 10 mg/kg chloroquine in combination with primaquine would be adequatein personswith no chloroquinein
theirblood before therapy.
Primaquineat therapeuticdoses has long been considered
an exclusivelytissue-schizonticidaldrug,that is, eliminating
infectedhepatocyteswithoutkillingblood-stageasexualparasites [5]. AfterstudiesI and II, we consideredthe possibility
that primaquineworkedby preventingearly relapseor reinfection but not by attackinginfected erythrocytes.However,
we believe that when primaquineis used with chloroquine
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againstresistantP. vivax,the efficacyof this combinationis
due to activity directedagainst infected erythrocytesrather
than infectedhepatocytes.If the high therapeuticfailurerate
in the chloroquineplus placebogroupsis linkedto resistance
to chloroquineby asexualblood formsof P. vivax,then superiorefficacyof chloroquineplus primaquineagainstresistant
blood-stageparasiteswould explain the low rateof therapeutic failure.
Several observationsshow that blood-stage resistanceto
chloroquineby P. vivaxpredominatedamong the patientsin
Irian Jaya. First, among 312 patients infected by P. vivax
(most acquirednaturallyin tropicalAsia and the South Pacific), none had a recurrentparasitemiabefore day 17 after
initiating demonstrably effective quinine therapy [6-12].
Therefore,recurrentparasitemiaswithin 14 days of starting
chloroquinetherapy,as among 44%of patientsgiven chloroquine plus placebo,almostcertainlyrepresentrecrudescence
by P. vivax.Second, among 245 patientsinfected by P. vivax
from the southwestPacificduringWorld War II and treated
with chloroquine,none had recurrentparasitemiabeforeday
30 after the start of therapy[6-12]. Therefore,recurrences
within 30 days of startingchloroquinetherapyconstitutedirect evidence of resistance;the 28-day cumulativeincidence
of recurrentparasitemiaamong the patientsin IrianJayawas
70%(crude failure rate of 78%,i.e., 35 failuresamong 45
complete tests). All except 3 recurrencesof parasitemiain
our studiesoccurredin the face of ordinarilysuppressivelevels of chloroquinein blood (figure 1).
Third,exposureof the studysubjectsto reinfectionduring
our studieswas much too low to account for the differences
between the primaquineand placebogroups.In two studies,
the incidence of P. vivaxin the Arso region rangedfrom 0.6
to 1.25 infections/person-year[ 13]. Thus, amongthe 50 subjects in the chloroquine plus placebo groups (3.8 personyears of follow-up), 4 reinfections would be expected,
whereas 35 recurrencesappeared. In summary,relapse or
reinfectioncould not account for the very largedifferencein
therapeuticfailure rates between the chloroquineplus placebo and chloroquineplus primaquinegroups,both containing subjectsinfectedwith ~70% chloroquine-resistantP. vivax.The basisof that differenceappearsto be superiorblood
schizonticidalactivity by chloroquineplus primaquineversus chloroquineplus placebo.
Combinedchloroquineand primaquinetherapyact addiP. vivax
tively or synergisticallyagainstchloroquine-resistant
infections.Studiesof chloroquineand primaquinetreatment
of the chloroquine-resistantNS strainof Plasmodiumyoelii
in mice supportthe interpretationof synergy[14]. A clinical
study of P. vivaxin Thailand showed surprisingblood schizonticidal activity of primaquinealone [ 15], but those patients could have had low levels of self-administeredchloroquine in theirblood. Determinationof whetherchloroquine
and primaquinefunctionadditivelyor synergisticallyagainst
chloroquine-resistantP. vivaxand of how much activitypri-
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maquine actually has on its own against chloroquine-resistant P. vivaxmust await furtherinvestigation.
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